Selling Science: Polio and the Promise of Gamma Globulin

Stephen E. Mawdsley

Research output: Book/ReportBook

Abstract

Today, when many parents seem reluctant to have their children vaccinated, even with long proven medications, the Salk vaccine trial, which enrolled millions of healthy children to test an unproven medical intervention, seems nothing short of astonishing. In Selling Science, medical historian Stephen E. Mawdsley recounts the untold story of the first large clinical trial to control polio using healthy children—55,000 healthy children—revealing how this long-forgotten incident cleared the path for Salk’s later trial.

Mawdsley describes how, in the early 1950s, Dr. William Hammon and the National Foundation for Infantile Paralysis launched a pioneering medical experiment on a previously untried scale. Conducted on over 55,000 healthy children in Texas, Utah, Iowa, and Nebraska, this landmark study assessed the safety and effectiveness of a blood component, gamma globulin, to prevent paralytic polio. The value of the proposed experiment was questioned by many prominent health professionals as it harbored potential health risks, but as Mawdsley points out, compromise and coercion moved it forward. And though the trial returned dubious results, it was presented to the public as a triumph and used to justify a federally sanctioned mass immunization study on thousands of families between 1953 and 1954. Indeed, the concept, conduct, and outcome of the GG study were sold to health professionals, medical researchers, and the public at each stage. At a time when most Americans trusted scientists, their mutual encounter under the auspices of conquering disease was shaped by politics, marketing, and at times, deception.

Drawing on oral history interviews, medical journals, newspapers, meeting minutes, and private institutional records, Selling Science sheds light on the ethics of scientific conduct, and on the power of marketing to shape public opinion about medical experimentation.
LanguageEnglish
Place of PublicationNew Brunswick, New Jersey
Number of pages232
Publication statusPublished - 1 Aug 2016

Publication series

NameCritical Issues in Health and Medicine

Fingerprint

Polio
Marketing
Health Professionals
Experiment
Compromise
1950s
Clinical Trials
Health
Historian
Oral History
Medical Journals
Coercion
Blood
Public Opinion
Experimentation
Vaccine
Safety
Medical Sciences
Medication
Deception

Keywords

  • gamma globulin
  • polio
  • clinical trials
  • medical ethics
  • immunization
  • Jonas Salk
  • William Hammon

Cite this

Mawdsley, S. E. (2016). Selling Science: Polio and the Promise of Gamma Globulin. (Critical Issues in Health and Medicine). New Brunswick, New Jersey.
Mawdsley, Stephen E. / Selling Science : Polio and the Promise of Gamma Globulin. New Brunswick, New Jersey, 2016. 232 p. (Critical Issues in Health and Medicine).
@book{699651ef6ffd4f4daab340365ec64ff3,
title = "Selling Science: Polio and the Promise of Gamma Globulin",
abstract = "Today, when many parents seem reluctant to have their children vaccinated, even with long proven medications, the Salk vaccine trial, which enrolled millions of healthy children to test an unproven medical intervention, seems nothing short of astonishing. In Selling Science, medical historian Stephen E. Mawdsley recounts the untold story of the first large clinical trial to control polio using healthy children—55,000 healthy children—revealing how this long-forgotten incident cleared the path for Salk’s later trial. Mawdsley describes how, in the early 1950s, Dr. William Hammon and the National Foundation for Infantile Paralysis launched a pioneering medical experiment on a previously untried scale. Conducted on over 55,000 healthy children in Texas, Utah, Iowa, and Nebraska, this landmark study assessed the safety and effectiveness of a blood component, gamma globulin, to prevent paralytic polio. The value of the proposed experiment was questioned by many prominent health professionals as it harbored potential health risks, but as Mawdsley points out, compromise and coercion moved it forward. And though the trial returned dubious results, it was presented to the public as a triumph and used to justify a federally sanctioned mass immunization study on thousands of families between 1953 and 1954. Indeed, the concept, conduct, and outcome of the GG study were sold to health professionals, medical researchers, and the public at each stage. At a time when most Americans trusted scientists, their mutual encounter under the auspices of conquering disease was shaped by politics, marketing, and at times, deception.Drawing on oral history interviews, medical journals, newspapers, meeting minutes, and private institutional records, Selling Science sheds light on the ethics of scientific conduct, and on the power of marketing to shape public opinion about medical experimentation.",
keywords = "gamma globulin, polio, clinical trials, medical ethics, immunization, Jonas Salk, William Hammon",
author = "Mawdsley, {Stephen E.}",
year = "2016",
month = "8",
day = "1",
language = "English",
isbn = "978-0-8135-7439-4",
series = "Critical Issues in Health and Medicine",

}

Mawdsley, SE 2016, Selling Science: Polio and the Promise of Gamma Globulin. Critical Issues in Health and Medicine, New Brunswick, New Jersey.

Selling Science : Polio and the Promise of Gamma Globulin. / Mawdsley, Stephen E.

New Brunswick, New Jersey, 2016. 232 p. (Critical Issues in Health and Medicine).

Research output: Book/ReportBook

TY - BOOK

T1 - Selling Science

T2 - Polio and the Promise of Gamma Globulin

AU - Mawdsley, Stephen E.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Today, when many parents seem reluctant to have their children vaccinated, even with long proven medications, the Salk vaccine trial, which enrolled millions of healthy children to test an unproven medical intervention, seems nothing short of astonishing. In Selling Science, medical historian Stephen E. Mawdsley recounts the untold story of the first large clinical trial to control polio using healthy children—55,000 healthy children—revealing how this long-forgotten incident cleared the path for Salk’s later trial. Mawdsley describes how, in the early 1950s, Dr. William Hammon and the National Foundation for Infantile Paralysis launched a pioneering medical experiment on a previously untried scale. Conducted on over 55,000 healthy children in Texas, Utah, Iowa, and Nebraska, this landmark study assessed the safety and effectiveness of a blood component, gamma globulin, to prevent paralytic polio. The value of the proposed experiment was questioned by many prominent health professionals as it harbored potential health risks, but as Mawdsley points out, compromise and coercion moved it forward. And though the trial returned dubious results, it was presented to the public as a triumph and used to justify a federally sanctioned mass immunization study on thousands of families between 1953 and 1954. Indeed, the concept, conduct, and outcome of the GG study were sold to health professionals, medical researchers, and the public at each stage. At a time when most Americans trusted scientists, their mutual encounter under the auspices of conquering disease was shaped by politics, marketing, and at times, deception.Drawing on oral history interviews, medical journals, newspapers, meeting minutes, and private institutional records, Selling Science sheds light on the ethics of scientific conduct, and on the power of marketing to shape public opinion about medical experimentation.

AB - Today, when many parents seem reluctant to have their children vaccinated, even with long proven medications, the Salk vaccine trial, which enrolled millions of healthy children to test an unproven medical intervention, seems nothing short of astonishing. In Selling Science, medical historian Stephen E. Mawdsley recounts the untold story of the first large clinical trial to control polio using healthy children—55,000 healthy children—revealing how this long-forgotten incident cleared the path for Salk’s later trial. Mawdsley describes how, in the early 1950s, Dr. William Hammon and the National Foundation for Infantile Paralysis launched a pioneering medical experiment on a previously untried scale. Conducted on over 55,000 healthy children in Texas, Utah, Iowa, and Nebraska, this landmark study assessed the safety and effectiveness of a blood component, gamma globulin, to prevent paralytic polio. The value of the proposed experiment was questioned by many prominent health professionals as it harbored potential health risks, but as Mawdsley points out, compromise and coercion moved it forward. And though the trial returned dubious results, it was presented to the public as a triumph and used to justify a federally sanctioned mass immunization study on thousands of families between 1953 and 1954. Indeed, the concept, conduct, and outcome of the GG study were sold to health professionals, medical researchers, and the public at each stage. At a time when most Americans trusted scientists, their mutual encounter under the auspices of conquering disease was shaped by politics, marketing, and at times, deception.Drawing on oral history interviews, medical journals, newspapers, meeting minutes, and private institutional records, Selling Science sheds light on the ethics of scientific conduct, and on the power of marketing to shape public opinion about medical experimentation.

KW - gamma globulin

KW - polio

KW - clinical trials

KW - medical ethics

KW - immunization

KW - Jonas Salk

KW - William Hammon

UR - http://www.selling-science.org/

UR - http://rutgerspress.rutgers.edu/product/Selling-Science,5817.aspx

M3 - Book

SN - 978-0-8135-7439-4

T3 - Critical Issues in Health and Medicine

BT - Selling Science

CY - New Brunswick, New Jersey

ER -

Mawdsley SE. Selling Science: Polio and the Promise of Gamma Globulin. New Brunswick, New Jersey, 2016. 232 p. (Critical Issues in Health and Medicine).